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Abstract–	
The	cytokine	interleukin	(IL)-6	is	a	major	therapeutic	target	for	the	treatment	of	various	inflammatory	
and	autoimmune	diseases.	While	IL-6	receives	considerable	attention	in	studies	of	innate	and	adaptive	
immunity,	 the	 IL-6-related	 family	 member	 IL-27	 is	 increasingly	 recognized	 for	 its	 effects	 on	 cellular	
proliferation,	 differentiation	 and	 leukocyte	 effector	 functions.	 Both	 cytokines	 activate	 responses	 in	
myeloid	 and	 stromal	 tissue	 cells	where	 they	 direct	 the	 transition	 from	 innate	 to	 adaptive	 immunity.	
However,	they	are	frequently	identified	as	lymphokines	that	control	responses	in	T	cells	and	B	cells.	In	
this	 regard,	 IL-27	 often	 opposes	 the	 action	 of	 IL-6.	Here,	we	will	 review	 the	 role	 of	 IL-6	 and	 IL-27	 in	
inflammation,	 with	 a	 particular	 focus	 on	 inflammatory	 arthritis,	 and	 discuss	 their	 importance	 in	 the	
diagnosis,	stratification	and	treatment	of	autoimmune	disease.		
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The	IL-6	family	of	cytokines	–	
All	members	 of	 the	 interleukin	 (IL)-6	 family	 share	 a	 common	 130kDa	 glycoprotein	 signal-transducing	
receptor	 (gp130,	CD130).	 In	 this	 regard,	 receptors	 for	 IL-11,	oncostatin-M	(OSM),	ciliary	neurotrophic	
factor	 (CNTF),	 cardiotrophin-1	 (CT-1),	 leukemia	 inhibitory	 factor	 (LIF)	 and	 the	 cardiotrophin-like	
cytokine	 (CLC)	 all	 utilize	 gp130	 to	 transmit	 cytokine	 responses.	 These	 IL-6-related	 cytokines	 are	
structurally	 related	 and	 each	 contain	 4	 long	α-helical	 chains,	which	 are	 arranged	 in	 an	 up-up-down-
down	topography	[1].	In	contrast,	the	IL-6-related	cytokine	IL-27	is	a	heterodimeric	cytokine	consisting	
of	 two	 independent	 subunits	 termed	 IL-27p28	 (also	 known	 as	 IL-30)	 and	 EBI3	 [2].	 IL-27	 therefore	
resembles	IL-12	(which	comprises	IL-12p40	and	IL-12p35),	and	the	related	IL-23	(IL-23p19	and	IL-12p40)	
and	IL-35	(IL-12p40	and	EBI3)	inflammatory	cytokines	(Figure-1)	[3].	However,	IL-27	also	shares	several	
characteristics	 common	to	 the	 IL-6	cytokine	 family.	First,	 the	 receptor	complex	 for	 IL-27	contains	 the	
IL-27	 receptor-α	 (IL-27Rα,	 also	 known	 as	WSX-1	 and	 TCCR)	 subunit	 together	 with	 gp130	 [4].	 While	
gp130	 is	 universally	 expressed	 in	 all	 tissues	 and	 organs,	 IL-27Rα	 is	mostly	 restricted	 to	 lymphocytes,	
monocytes	and	osteoclasts	[1,	3].	The	cognate	α-subunit	of	the	IL-6	receptor	(IL-6R,	CD126)	also	shows	
a	 similarly	 restricted	 pattern	 of	 expression	 and	 is	 found	 on	 hepatocytes,	 leukocyte	 subsets	 and	
megakaryocytes	 [5].	 Second,	EBI3	 shares	 close	 sequence	 identity	with	 IL-6R	 [3,	6].	 In	 this	 regard,	 the	
soluble	IL-6R	when	bound	to	IL-6	resembles	a	heterodimeric	cytokine	reminiscent	of	IL-12,	IL-23,	IL-27	
and	 IL-35	 [5-7].	 Third,	 IL-6	 and	 IL-27	 receptor	 activation	 leads	 to	 signaling	 through	 the	 latent	
transcription	 factors	 Signal	 Transducer	 and	 Activator	 of	 Transcription-1	 (STAT1)	 and	 STAT3	 [8].	
Interleukin-27	is	however	the	only	member	of	the	IL-6-related	cytokine	family	to	predominantly	signal	
via	STAT1	instead	of	STAT3	[1,	3].	Consequently	IL-6	and	IL-27	elicit	both	common	and	distinct	biological	
outcomes,	and	IL-27	can	often	limit	IL-6/STAT3-driven	events.		
	
The	inflammatory	significance	of	IL-6	and	IL-27	–	
Based	on	the	biological	properties	of	IL-6,	this	cytokine	was	originally	named	interferon	β2,	hepatocyte	
stimulating	 factor,	 cytotoxic	 T	 cell	 differentiation	 factor,	 B	 cell	 differentiation	 factor	 and	 B	 cell	
stimulatory	 factor-2.	These	broad	definitions	 identify	 IL-6	as	a	 lymphokine	and	activator	of	 the	acute	
phase	 response	 [5].	 However,	 clinical	 experience	 with	 the	 blocking	 anti-IL-6R	 monoclonal	 antibody	
tocilizumab	 has	 helped	 unearth	 roles	 for	 IL-6	 in	 the	 control	 of	 lipid,	 glucose	 and	 iron	 metabolism,	
regulation	 of	 the	 neuroendocrine	 system,	 and	 changes	 in	 psychological	 wellbeing	 that	 include	 pain,	
fatigue,	 mood	 and	 depression	 (Figure-2)	 [5].	 Thus,	 IL-6	 often	 displays	 features	 of	 a	 hormone.	 In	
contrast,	IL-27	is	primarily	associated	with	the	control	of	innate	and	adaptive	immunity	to	infection	[3,	
9].	 Interleukin-27	was	first	recognized	as	a	pro-inflammatory	cytokine	due	to	its	ability	to	support	the	
development	of	 interferon	(IFN)-γ	 secreting	T-helper	cells.	For	example,	 IL-27	promotes	expression	of	
IFN-γ,	 the	 transcriptional	 master	 regulator	 T-bet,	 STAT1	 and	 IL-12Rβ2	 [2,	 8,	 10-12].	 These	 activities	
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closely	 resemble	 those	 of	 IL-12.	 However,	 subsequent	 studies	 have	 shown	 that	 IL-27	 is	 a	 negative	
regulator	of	IL-2	and	can	restrict	development	of	immune	responses	(Figure-3)	[13-18].	For	example,	IL-
27	 is	 required	 for	 the	 development	 of	 T-bet+,	 CXCR3+	 Treg	 populations	 following	 Th1-mediated	
inflammation	 using	 Toxoplasma	 gondii	 challenged	 IL-27R-deficient	mice	 [14].	 In	 this	 regard	 the	 anti-
inflammatory	properties	of	type-I	interferons	are	largely	attributed	to	the	upregulation	of	IL-27	and	the	
subsequent	 promotion	 of	 IL-10	 [19-21].	 Consistent	 with	 these	 observations,	 prominent	
immunosuppressive	roles	were	discovered	for	IL-27	through	investigations	in	mouse	models	of	chronic	
infection	and	autoimmunity	 [22-26].	 In	 the	absence	of	a	 regulatory	 IL-27	signal,	 IL-27R-deficient	mice	
developed	 profound	 or	 lethal	 T	 cell-mediated	 pathology	 [13,	 16,	 27,	 28].	 In	 this	 context	 IL-27	 often	
antagonises	 the	 actions	 of	 IL-6.	While	 IL-6	 supports	 the	 development	 and	 expansion	 of	 T	 helper	 cell	
responses	[5],	IL-27	has	emerged	as	an	inhibitor	of	Th17	activities	and	in	a	model	of	helminth	infection	
limits	 Th2	 responses	 through	 inhibiting	 GATA3	 expression	 (Figure-3)	 [8,	 18,	 29].	 While	 additional	
investigations	are	required	to	 fully	explore	the	wider	biological	 functions	of	 IL-27,	emerging	data	also	
highlight	potential	roles	for	IL-27	in	the	control	of	pain	[30],	myeloid	cell	activation	[31-37]	and	stromal	
tissue	responses	(Figure-2)	[38-40].	Thus,	IL-6	and	IL-27	contribute	to	inflammation	and	the	regulation	
of	both	innate	and	adaptive	immune	responses.		
	
Although	the	receptor	complex	for	IL-27	signaling	remains	fixed,	composed	of	IL-27Rα	and	gp130,	the	
signaling	mechanisms	 employed	 by	 IL-6	 are	 highly	 complex	 (Figure-1),	 and	 it	 is	 often	 challenging	 to	
understand	 how	 IL-6	 receptor	 signaling	 can	 elicit	 a	 diverse	 array	 of	 biological	 responses.	 Three	 very	
distinct	 forms	 of	 IL-6	 receptor	 signaling	 have	 now	 been	 proposed.	 These	 are	 termed	 classical	 IL-6	
receptor	signaling,	IL-6	trans-signaling,	which	is	reliant	on	the	presence	of	a	soluble	form	of	IL-6R	(sIL-
6R),	and	a	newly	reported	mechanism	called	IL-6	trans-presentation	[5,	41,	42].	In	contrast,	IL-27	uses	a	
classical	IL-27	receptor	system	based	on	the	cellular	expression	of	IL-27Rα	and	gp130.	However,	the	IL-
27p28	subunit	of	 IL-27	has	also	been	 reported	 to	antagonize	 IL-6-mediated	T	cell	 responses,	and	can	
potentially	 bind	 the	 IL-6R	 (Figure-1)	 [18,	 43,	 44].	 So	 why	 does	 IL-6	 adopt	 these	 different	 forms	 of	
signaling?	 Here,	 it	 is	 important	 to	 note	 that	 IL-6	 contributions	 to	 both	 the	 regulation	 of	 immune	
homeostasis	and	inflammatory	responses	are	relevant	to	infection,	trauma	or	injury	[5].	During	health,	
classical	 IL-6	 receptor	 signaling	 promotes	 the	 maintenance	 of	 normal	 physiology.	 For	 example,	 IL-6	
controls	 various	metabolic	 processes	 and	 tissue	 renewal	 or	 regeneration	 [5].	 In	 contrast,	 IL-6	 trans-
signaling	 is	more	widely	associated	with	the	regulation	of	 inflammatory	processes	relevant	to	disease	
[5,	41].	This	distinction	 is	not	however	black	and	white.	 In	this	regard,	classical	 IL-6	receptor	signaling	
controls	both	the	acute	phase	response	and	the	generation	of	certain	effector	CD4	T	cell	populations	
[5].	 Similarly,	 IL-6	 trans-signaling	has	been	 linked	 to	processes	 including	hematopoiesis	and	 the	 sleep	
REM	cycle	[45,	46].	The	newly	described	IL-6	trans-presentation	mode	of	cell	activation	is	a	juxtacrine	
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mechanism	of	 IL-6	 signaling	 that	promotes	 the	engagement	of	dendritic	 cells	with	T	 cells	 [42].	While	
further	work	 is	 required	to	establish	 the	precise	biological	 significance	of	 IL-6	 trans-presentation,	 this	
mode	of	cell	activation	may	control	 immunological	processes	 in	 tissues	 that	 rely	on	resident	 immune	
cells	 to	mount	 an	 appropriate	 response	 to	 antigen	 challenge.	 These	 locations	may	 include	 sites	with	
immune	privilege	such	the	brain	or	eye.		
		
In	 the	 accompanying	 sections,	 we	 will	 consider	 the	 roles	 of	 IL-6	 and	 IL-27	 in	 the	 progression	 of	
inflammatory	disease	and	will	focus	on	their	involvement	in	rheumatoid	arthritis.	
	
The	significance	of	genetic	polymorphisms	linked	with	IL-6	and	IL-27	–	
Several	lines	of	genetic	evidence	support	a	role	for	IL-6	and	IL-27	in	autoimmunity,	cancer	and	infection.	
Genome-wide	 association	 studies	 and	 analyses	 of	 genetic	 polymorphisms	 have	 identified	 several	
susceptibility	 loci	 relevant	to	 IL-6	and	 IL-27	that	predict	a	predisposition	for	autoimmune	disease.	For	
example,	a	single	nucleotide	polymorphism	proximal	to	the	IL6	(rs1800795)	transcriptional	start	site	is	
associated	with	an	increased	incidence	of	coronary	heart	disease,	idiopathic	juvenile	arthritis	and	other	
inflammatory	 conditions	 [47-50].	 Equally,	 genetic	 variants	 associated	with	 IL6st	 (gp130;	 rs10940495)	
and	IL6R	(rs2228145)	are	common	to	patients	with	cardiovascular	disease	and	rheumatoid	arthritis	[47-
50].	Several	polymorphisms	linked	with	IL27	(encoding	IL-27p28;	rs153109,	rs181206,	rs17855750)	also	
display	risk	susceptibilities	with	asthma,	certain	cancers,	metabolic	disorders	and	some	viral	infections	
[51-53].	 For	 example,	 rs153109	 is	 linked	 to	 more	 severe	 forms	 of	 rheumatoid	 arthritis	 [54].	 While	
additional	functional	genetic	studies	are	required	to	determine	the	biological	relevance	of	these	genetic	
variants,	 several	 contribute	 to	 changes	 in	 cytokine	 or	 cytokine	 receptor	 expression.	 For	 example,	
mutations	within	IL6R	(rs2228145)	and	IL6	(rs1800795)	contribute	to	elevations	in	circulating	sIL-6R	or	
IL-6,	 which	 reflected	 an	 altered	 risk	 of	 cardiovascular	 disease,	 enhanced	 susceptibility	 to	 insulin	
resistance,	obesity,	and	other	 inflammatory	complications	[47-50,	55-57].	Comparable	studies	of	 IL-27	
related	polymorphisms	require	further	investigation.	
	
The	therapeutic	opportunities	afforded	by	IL-6	and	IL-27	–	
The	 success	 of	 interleukin-6	 inhibitors	 in	 rheumatoid	 arthritis	 and	 related	 conditions	 illustrates	 the	
prominent	role	this	cytokine	plays	in	the	underlining	pathology.	There	are	now	several	biological	drugs	
that	 target	 the	 cytokine	 itself	 (e.g.,	 clazakizumab,	 olokizumab,	 vobarilizumab,	 sirukumab),	 the	 IL-6R	
(e.g.,	tocilizumab,	sarilumab),	or	the	soluble	form	of	IL-6R	(e.g.,	olamkicept)	[5].	Some	of	these	are	now	
approved	 for	 the	 treatment	 of	 rheumatoid	 arthritis,	 systemic	 juvenile	 arthritis,	 polyarticular	 juvenile	
idiopathic	arthritis,	giant	cell	arteritis,	and	Castleman’s	disease.	In	addition,	Janus	kinase	inhibitors	(e.g.,	
tofacitinib,	baracitinib,	ruxolitinib)	also	impact	IL-6	receptor	signaling	as	part	of	their	mode	of	action	[5,	
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41].	While	these	drugs	are	well	tolerated	and	offer	clinical	benefit,	the	development	of	sirukumab	was	
recently	stopped	following	a	negative	review	from	the	FDA.	However,	the	anti-inflammatory	properties	
of	 IL-27	 suggests	 that	 an	 IL-27	 supplementation	 intervention	 may	 offer	 an	 alternate	 therapeutic	
strategy.	 For	 example,	 studies	 in	 experimental	models	 of	 inflammatory	 arthritis,	 and	 ex	 vivo	 culture	
systems	show	that	 IL-27	 inhibits	the	expansion	of	 IL-17	secreting	CD4	T	cells	(Th17	cells),	restricts	the	
development	of	ectopic	 lymphoid	aggregates,	and	can	 reduce	 the	 severity	of	 joint	damage	and	bone	
erosion	[58-60].	No	clinical	trials	have	however	been	conducted	to	explore	this	approach	in	more	detail.	
A	 similar	 strategy	 was	 previously	 adopted	 to	 test	 the	 anti-arthritic	 properties	 of	 recombinant	 IL-11.	
However	clinical	 trials	with	recombinant	 IL-11	 in	 rheumatoid	arthritis	 failed	to	reach	clinical	endpoint	
and	 were	 suspended	 [61].	 The	 biology	 of	 IL-27,	 and	 its	 particular	 influence	 on	 adaptive	 immune	
responses	(Figure-3),	means	that	IL-27	may	be	a	more	attractive	intervention	therapy.		
	
In	rheumatoid	arthritis,	synovial	IL-6	and	IL-27	levels	correspond	with	differences	in	disease	activity	[58,	
62-64].	 For	 example,	 IL-6	 expression	 correlates	with	 poor	 disease	 prognosis	 including	 elevated	 acute	
phase	 activity,	 fatigue	 and	 increased	 cardiovascular	 risk.	 In	 contrast,	 synovial	 IL-27	 levels	 correspond	
with	a	reduction	 in	 IL-17	and	 IL-6,	and	the	Th17	chemoattractant	CCL20	[62].	Thus,	elevated	 levels	of	
synovial	 IL-27	 in	 inflamed	 rheumatoid	 arthritis	 joints	may	 reflect	 an	effort	 to	 counteract	 a	 persistent	
adaptive	 immune	 response.	 These	 findings	 are	 also	 reflected	 by	 studies	 in	 mice.	 Histological	
assessments	 of	 joint	 synovitis	 revealed	 that	 local	 IL-27-treatment	 resulted	 in	 suppressed	 leukocyte	
infiltration,	 synovial	 hyperplasia,	 cartilage	 and	 bone	 erosion,	 vascularization,	 and	 IL-6	 and	 IL-17	
expression	 in	 inflamed	 joints	 [59].	 Systemic	 administration	 of	 IL-27	 during	 collagen-induced	 arthritis	
also	reduced	type	II	collagen-specific	antibody	titers	and	serum	levels	of	IL-17	and	IL-6	[58].	Analysis	of	
the	peripheral	 immune	CD4	T	cell	 response	also	revealed	that	 IL-27	 inhibited	the	generation	of	 IL-17-
producing	 collagen-specific	 T	 cells,	 but	 promoted	 an	 increase	 in	 IL-10	 secreting	 CD4	 T	 cells	 and	
suppressive	regulatory	T	 (Treg)	cells	 that	 regulate	the	expression	of	cytotoxic	T-lymphocyte	antigen	4	
(CTLA-4)	 and	 programmed	 cell	 death	 protein	 1	 (PD-1)	 [65].	 Interestingly,	 mice	 lacking	 IL-12p35	 also	
develop	 a	mild	 form	 of	 antigen-induced	 arthritis.	 This	 was	 attributed	 to	 an	 increased	 production	 of	
IL-27	and	IL-10,	and	the	expansion	of	Treg	cells	[66].	In	this	regard,	IL-12p35	acts	to	suppress	the	action	
of	IL-27	during	inflammatory	arthritis,	and	blockade	of	IL-27	activity	was	shown	to	restore	the	severity	
of	 synovitis	 [66].	 The	 above	 studies	 highlight	 the	 therapeutic	 potential	 of	 IL-27	 for	 the	 treatment	 of	
inflammatory	arthritis	and	other	diseases	associated	with	autoimmune	T	cell-mediated	pathology.	
	
IL-6	and	IL-27	in	inflammatory	arthritis	–	
Interleukin-6	is	the	archetypal	member	in	the	IL-6-related	cytokine	family.	While	many	of	these	factors	
elicit	 similar	 biological	 responses	 in	 vitro,	 IL-6	 often	 displays	 an	 over-riding	 influence	 on	 the	 same	
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responses	 in	 vivo.	 Experiments	 in	 animal	 models	 show	 that	 IL-6-deficient	 mice	 are	 protected	 from	
various	 forms	 of	 disease	 [5,	 41,	 67].	 For	 example,	 the	 induction	 of	 inflammatory	 arthritis	 in	 IL-6	
deficiency	is	associated	with	an	absence	of	synovial	infiltration,	synovial	hyperplasia	and	joint	damage	
(reviewed	 in	 [67]).	 This	 is	 not	 true	 for	 other	 cytokines	 in	 the	 IL-6	 family.	 In	models	 of	 arthritis,	 IL-11	
Receptor-α	 (IL-11Rα)-KO	 mice	 and	 OSM	 Receptor-β	 (OSMRβ)-KO	 mice	 develop	 disease	 severity	
comparable	 to	 wild	 type	 controls	 [68].	 However,	 there	 may	 be	 a	 context	 dependent	 caveat	 to	 this	
generalization	 [69-72].	 For	 example,	 interleukin-11	 regulates	 many	 anti-inflammatory	 outcomes	 in	
arthritis,	 which	 fuelled	 the	 aforementioned	 clinical	 trials	 with	 recombinant	 IL-11	 [61,	 73,	 74].	 The	
relationship	between	 IL-6	and	 IL-27	 is	however	different.	 In	models	of	 inflammation,	 IL-27	deficiency	
contributes	 to	 a	 more	 active	 pathology	 that	 includes	 the	 development	 of	 a	 more	 severe	 form	 of	
synovitis,	and	enhanced	adaptive	immune	responses	that	are	reflected	by	an	increase	in	effector	CD4	T	
cell	numbers	and	antibody	responses	[60].	Thus,	IL-6	and	IL-27	acting	via	a	common	signaling	receptor	
subunit	 elicit	 contrasting	 inflammatory	 outcomes	 that	 influence	 the	 initiation,	 maintenance	 and	
severity	of	joint	pathology.	While	these	activities	primarily	pertain	to	the	control	of	adaptive	immunity,	
both	cytokines	have	influences	on	stromal	tissue	responses	to	inflammation.	For	example,	IL-6	and	IL-
27	 play	 important	 roles	 in	 bone	 remodeling,	 where	 an	 imbalance	 between	 bone	 resorption	 and	
formation	contributes	to	bone	destruction	in	inflammatory	arthritis	[75-78].	Here,	Il27ra	deficient	mice	
with	 experimental	 arthritis	 displayed	 severe	 synovitis	 and	 synovial	 hyperplasia,	 and	 an	 increased	
incidence	 of	 focal	 bone	 erosions	 [60].	 Systemic	 delivery	 of	 IL-27	 reversed	 the	 development	 of	 these	
inflammatory	 parameters	 and	 inhibited	 osteoclastogenesis	 [79].	 Notably,	 the	 action	 of	 IL-27	 on	
inflammation-driven	 bone	 destruction	 can	 be	 both	 direct	 and	 indirect.	 For	 example,	 IL-27	 abrogates	
RANKL	 responsiveness	 in	 osteoclast	 precursors	 and	 suppresses	 signaling	 downstream	 of	 RANK	 [36].	
Interleukin-27	has	also	been	shown	 to	 inhibit	 the	production	of	RANKL	 in	activated	CD4+	T	cells	 [80].	
The	 impact	 of	 IL-27	 on	 bone	 turnover	 is	 however	 not	 unexpected,	 and	 other	 IL-6	 related	 cytokines	
including	IL-11,	OSM,	LIF	and	CNTF	also	control	aspects	of	bone	homeostasis	[81-84].	In	summary,	both	
IL-6	 and	 IL-27	 contribute	 to	 the	 control	 of	 synovitis	 and	 associated	 changes	 in	 cartilage	 and	 bone	
erosion.	
	
IL-27	suppresses	synovial	ectopic	lymphoid-like	structure	development	–	
Interleukin-6	 and	 IL-27	 are	 both	 lymphokines	 that	 control	 the	 survival,	 proliferation	 and	 effector	
characteristics	of	T	 cells	and	B	cells	and	are	 thus	poised	 to	 shape	adaptive	 immune	 responses	within	
inflamed	joints.	IL-6	has	long	stood	as	a	key	mediator	in	the	generation	of	antibody	responses	and	the	
formation	of	germinal	center	reactions	[85,	86].	Recent	studies	have	also	highlighted	the	importance	of	
B	 cell-derived	 IL-6	 in	 promoting	 class-switch	 recombination	 of	 autoantibodies	 and	 spontaneous	
germinal	center	formation	that	are	required	for	establishing	systemic	lupus	erythematosus	in	mice	[87].	
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While	IL-27	has	also	been	shown	to	drive	the	secretion	of	IL-21	in	T	follicular	helper	cells	and	support	
germinal	center	function	[88],	the	IL-27p28	subunit	can	counteract	IL-6-driven	antibody	responses	and	
inhibit	germinal	center	development	[43].	Consistent	with	these	roles,	overexpression	of	IL-6	and	the	IL-
6R	in	mice	results	in	spontaneous	inflammation	featuring	the	formation	of	lymph	node-like	structures	
in	the	lung	[89].	Similar	lymphocytic	aggregates	called	ectopic	lymphoid-like	structures	(ELS;	also	called	
tertiary	lymphoid	structures,	TLS)	are	a	histopathological	hallmark	of	tissue	inflammation	in	a	number	
of	 autoimmune	 diseases,	 cancers	 and	 infection	 [90].	 New	 approaches	 such	 as	 ultrasound-directed	
small-needle	 synovial	 biopsy,	 combined	with	 histopathological	 assessment	 of	 joint	 inflammation,	 has	
provided	new	 insight	 into	disease	heterogeneity	 in	 rheumatoid	 arthritis	 [91].	Here,	 based	on	 cellular	
and	molecular	signatures,	synovitis	can	be	classed	into	three	pathotypes	called	‘follicular’,	‘diffuse’	and	
‘pauci-immune’.	While	diffuse	pathology	is	characterized	by	a	typical	random	infiltration	of	leukocytes	
primarily	 composed	 of	 macrophages	 and	 some	 T	 cells,	 the	 follicular	 pathotype	 features	 highly-
organized	 and	 segregated	 aggregates	 of	 T	 and	 B	 cells	 accompanied	 by	 CD21+	 follicular	 dendritic	 cell	
networks,	active	germinal	centers	and	high	endothelial	venules	(HEV).	ELS	are	associated	with	the	local	
priming	of	immune	cells	and	autoantibody	responses	[92,	93].	
	
Notably,	our	recent	evaluation	of	IL27	and	EBI3	expression	(encoding	IL-27p28	and	EBI3	respectively)		in	
the	diffuse	 synovial	 pathotype	mirrored	previous	 studies	 that	 identified	 heightened	 levels	 of	 IL-27	 in	
rheumatoid	 arthritis	 joint	 tissues	 as	 compared	 with	 control	 osteoarthritis	 joints	 [60].	 However,	
compared	to	patients	with	diffuse	pathology,	the	follicular	form	of	disease	was	associated	with	reduced	
expression	of	IL27.	Notably,	IL27RA	was	highly	expressed	in	the	follicular	form	of	rheumatoid	arthritis,	
and	cells	expressing	the	IL-27R	were	localized	at	ELS.	These	observations	suggest	that	distinct	cytokine	
networks	govern	the	development	of	synovial	pathotypes,	and	that	 the	absence	of	a	 regulatory	 IL-27	
signal	may	contribute	to	the	development	of	a	follicular	form	of	disease	that	is	linked	with	severe	local	
and	peripheral	inflammation	and	inferior	responses	to	biological	therapy	(e.g.,	anti-TNF)	[94-96].	
	
Early	 investigations	 into	 the	 endogenous	 role	 of	 IL-27	 in	 inflammatory	 arthritis	 revealed	 a	 pro-
inflammatory	role	in	proteoglycan-induced	arthritis	[97].	While	this	observation	in	IL-27R-deficient	mice	
appears	to	contradict	the	therapeutic	effect	that	has	been	observed	following	treatment	with	IL-27	in	
experimental	arthritis	[58,	59,	65,	79,	98],	this	may	reflect	the	importance	of	a	robust	Th1	cell	response	
for	 driving	 the	 proteoglycan-induced	 arthritis	 model.	 Our	 studies	 using	 IL-27R-deficient	 mice	 in	 the	
mBSA	 antigen-induced	 arthritis	 model	 revealed	 that	 these	 mice	 develop	 exacerbated	 joint	
inflammation,	synovial	hyperplasia,	and	cartilage	and	bone	erosion	that	was	accompanied	by	elevated	
peripheral	 Th17	 cell	 and	mBSA-specific	 antibody	 responses	 [60].	 Reflecting	 the	observation	 that	 IL27	
expression	 was	 reduced	 in	 synovial	 biopsies	 from	 rheumatoid	 arthritis	 patients	 with	 a	 follicular-rich	
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form	of	 disease,	 IL-27R-deficient	mice	 developed	 synovial	 ectopic	 lymphoid-like	 structures	 that	were	
associated	with	 the	expression	of	homeostatic	 cytokines	 (e.g.,	Lta,	 Ltb)	and	chemokines	 (e.g.,	Cxcl13,	
Ccl21)	 [60].	 Thus,	 while	 IL-6	 can	 promote	 ELS	 development	 in	 inflamed	 tissues,	 IL-27	 is	 a	 negative	
regulator	of	ELS.	An	 inhibitory	role	 for	 IL-27	at	ELS	 is	consistent	with	observations	 in	other	models	of	
inflammation	that	have	linked	heightened	Th17-type	effector	responses	(e.g.,	elevated	expression	of	IL-
17,	 IL-17F,	 IL-22,	 IL-21)	with	ELS	development	 [99-101].	 ELS	development	 in	 antigen-induced	arthritis	
was	associated	with	the	local	expression	of	IL-17	and	IL-21	[60],	and	effector	cytokines	linked	with	the	
Th17	 programme	 (e.g.,	 IL-17F,	 IL-21,	 IL-23,	 IL-22)	 have	 also	 been	 implicated	 in	 synovial	 lymphoid	
neogenesis	in	clinical	rheumatoid	arthritis	[102].	The	inhibitory	control	of	effector	Th17-type	responses	
by	IL-27	may	therefore	offer	opportunities	to	identify	new	therapeutic	targets	for	the	treatment	of	the	
follicular	form	of	rheumatoid	arthritis.	
	
Concluding	remarks–		
Cytokines	 that	 signal	 via	 the	 Jak-STAT	pathway	are	 increasingly	viewed	as	 therapeutic	 targets	 for	 the	
treatment	 of	 autoimmune	 diseases,	 infection	 and	 cancer.	 These	 include	 drugs	 that	 block	 IL-6	 (e.g.,	
olokizumab,	 clazakizumab,	 tocilizumab),	 IL-12p40	 (e.g.,	 ustekinumab),	 IL-21,	 IL-23p19	 (e.g.,	
risankizumab,	 guselkumab,	 tildrakizumab,	mirikizumab)	 or	 GM-CSF	 (e.g.,	mavrilimumab)	 signaling,	 or	
members	 of	 the	 Jak	 protein	 family	 (e.g.,	 tofacitinib,	 baracitinib,	 ruxolitinib).	 When	 considering	 the	
immuno-modulatory	 or	 anti-inflammatory	 properties	 of	 IL-27	 it	 is	 tempting	 to	 consider	 how	 IL-27	
intervention	 would	 supplement	 these	 therapies.	 	 Here,	 the	 capacity	 of	 IL-27	 to	 inhibit	 Th17	
development,	 and	 to	 promote	 the	 expression	 of	 checkpoint	 regulators	 and	 Treg	 activity,	mirrors	 the	
therapeutic	 responses	 linked	 with	 tocilizumab	 treatment	 [3,	 5].	 However,	 further	 investigations	 are	
required	 to	assess	 the	 context-dependent	 inflammatory	activities	of	 IL-27.	 These	may	 require	 clinical	
trials	 in	 humans.	While	 primary	 clinical	 endpoints	 will	 undoubtedly	 fixate	 on	 improvements	 in	 local	
tissue	 inflammation	 and	 damage,	 the	 wider	 implications	 of	 systemic	 inflammation	 are	 becoming	
equally	 important.	For	example,	a	metabolic	shift	associated	with	the	systemic	activation	of	T	cells	 in	
PD-1-deficient	mice	was	recently	shown	to	impact	the	generation	of	brain	monoamines	and	changes	in	
emotional	behavior	[103].	In	this	respect,	the	bioactivity	of	IL-27	is	interesting	since	IL-27	promotes	the	
expression	of	PD-1	 ligand	PD-L1	 [104].	Thus,	an	 IL-27	 intervention	may	offer	opportunities	 to	explore	
whether	 IL-27	can	bring	about	 improvement	 in	disease	activity	and	patient	wellbeing.	Such	strategies	
would	 be	 relevant	 to	 clinical	 indications	 where	 IL-17	 or	 Th17	 driven	 outcomes	 promote	 disease	
progression	 (e.g.,	psoriasis).	The	question	 is	whether	supplementation	with	recombinant	 IL-27	can	be	
used	as	a	standalone	intervention	or	an	adjunct	therapy	in	conditions	where	biological	drugs	that	target	
IL-6,	IL-12,	IL-17	or	IL-23	are	effective.	Several	of	the	benefits	associated	with	IL-6	blockade	relate	to	the	
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impact	 of	 therapy	 on	 altered	 metabolic	 processes	 (e.g.,	 anaemia	 through	 altered	 iron	 metabolism),	
fatigue	and	patient	wellbeing.	It	is	unclear	whether	recombinant	IL-27	would	elicit	similar	outcomes.		
	
In	 summary,	 IL-6	 and	 IL-27	 appear	 to	work	 in	 coordinated	 fashion,	with	 IL-27	 often	 suppressing	 the	
action	 of	 IL-6.	 These	 differences	 in	 biological	 activities	 reflect	 changes	 in	 the	 control	 of	 transcription	
factors	 STAT1	and	STAT3	and	may	also	 relate	 to	differences	 in	 the	 cytokine	 receptor	 subunits.	While	
further	work	 is	 required	 to	 fully	appreciate	 the	associations	between	 IL-6	and	 IL-27,	 the	current	data	
offers	 interesting	perspectives	on	how	an	 IL-27	 intervention	may	 supplement	existing	biological	 drug	
therapies	against	IL-6,	or	members	of	the	IL-12	cytokine	family.		
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Figure	Legends-	
	
Figure-1	–	The	biological	relationship	between	IL-6	and	IL-27	
The	illustration	shows	the	composition	of	the	IL-6	and	IL-27	receptor	complexes,	and	identifies	
the	Signal	Transducer	and	Activator	of	Transcription	(STAT)	factors	triggered	by	both	cytokines.	
Note	the	inclusion	of	gp130	in	both	receptors,	and	preferential	induction	of	STAT1	and	STAT3	
activity	(Bold	text).	For	the	IL-6	receptor	cassette	the	reader	should	note	the	various	IL-6	and	
IL-6R	blocking	therapies	currently	 in	clinical	development	or	clinical	utility.	Proteins	displayed	
in	the	orange	box	indicate	biological	entities	that	have	been	reported	to	engage	with	the	IL-6	
receptor,	 albeit	 at	 low	 affinity.	 Cytokines	 listed	 in	 the	 blue	 box	 showcase	 the	 protein	
composition	of	IL-27	related	heterodimeric	cytokines.	Common	subunits	are	colour	coded.	The	
IL-6:sIL-6R	 (and	 that	of	p28:sIL-6R)	 complex	 is	not	however	 stable	and	 the	cytokine-receptor	
undergoes	association	and	re-association	(indicated	by	the	+	symbol).	
	
Figure-2	–	The	functional	properties	of	IL-6	and	IL-27	
The	 biological	 properties	 of	 IL-6	 and	 IL-27	 have	 been	 broadly	 categorized	 under	 the	 terms	
‘Inflammation’,	 ‘Homeostasis’,	 and	 ‘Wellbeing’.	 Defined	 activities	 have	 been	 listed	 for	 each	
category	and	the	heatmap	identifies	the	relative	contribution	of	IL-6	and	IL-27	to	each	of	these	
processes.	The	definition	of	the	colour	coding	 is	 listed.	 It	should	be	noted	that	 IL-6	and	IL-27	
may	 regulate	 similar	 or	 distinct	 outcomes	 in	 each	 process	 and	 the	 reader	 is	 referred	 to	 the	
manuscript	text	and	review	articles	relevant	to	IL-6	or	IL-27	(references	[3,5]).	
	
Figure-3	–	Immuno-modulatory	action	of	IL-27	and	the	interface	with	IL-6	
IL-27	and	IL-6	together	coordinate	adaptive	immune	responses,	often	with	opposing	biological	
outcomes.	 In	an	inflammatory	microenvironment,	and	supported	by	accessory	cytokines,	 IL-6	
can	promote	the	differentiation	of	Th1,	Th2,	Th22	and	Th17	cells.	In	contrast,	IL-27	counteracts	
the	 IL-6-driven	 expansion	of	 Th17	 cells	 and	 inhibits	 the	 development	 of	 Th2	 and	 Th22	 cells.	
However,	IL-6	and	IL-27	can	both	promote	the	secretion	of	IL-10	in	a	number	of	effector	T	cell	
subsets,	and	can	drive	the	production	of	IL-21	in	T	helper	cells.	IL-27	drives	immunosuppressive	
effector	 characteristics	 in	 T	 cells	 including	 the	expression	of	 the	 immune	 checkpoints	PD-L1,	
PD1	and	CTLA4.	 In	 contrast	 to	 the	 inhibitory	action	of	 IL-6	on	Treg	 cells,	 IL-27	promotes	 the	
development	 of	 IL-10-producing	 T-bet+CXCR3+	 Treg	 cells	 and	 Tr1	 cells.	 IL-27	 also	 has	
immunosuppressive	roles	at	the	DC:T	cell	synapse,	for	example	through	promoting	expression	
of	PD-L1	on	DCs	and	inhibiting	MHC-I	expression.	Boxed	areas	highlight	opposing	roles	of	IL-27	
and	IL-6.	Figure	adapted	from	Yoshida	et	al.	(reference	[3]).	
	
